Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H13O3.Na |
| Molecular Weight | 264.2517 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(C([O-])=O)C1=CC=CC(OC2=CC=CC=C2)=C1
InChI
InChIKey=WVKIYGXHDKTNFO-UHFFFAOYSA-M
InChI=1S/C15H14O3.Na/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h2-11H,1H3,(H,16,17);/q;+1/p-1
| Molecular Formula | C15H13O3 |
| Molecular Weight | 241.2619 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00573Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Sources: http://www.drugbank.ca/drugs/DB00573
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00573 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
105.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Reaction gastrointestinal, Reaction skin... Other AEs: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Reaction gastrointestinal (2%) Other AEs:Reaction skin (1%) Cardiovascular disorder (NOS) (0.5%) Dyspepsia (10%) Sources: Nausea (7.7%) Constipation (7%) Vomiting (2.6%) Abdominal pain (2%) Diarrhea (1.8%) Headache (8.7%) Somnolence (8.5%) Dizziness (6.5%) Tremor (2.2%) Confusion (1.4%) Sweating increased (4.6%) Pruritus (4.2%) Rash (3.7%) Tinnitus (4.5%) Blurred vision (2.2%) Hearing decreased (1.6%) Palpitations (2.5%) Nervousness (5.7%) Asthenia (5.4%) Peripheral edema (5%) Dyspnea (2.8%) Fatigue (1.7%) Upper respiratory infection (1.5%) Nasopharyngitis (1.2%) Gastritis (<1%) Ulcer peptic with perforation (<1%) Ulcer peptic with perforation (<1%) Gastrointestinal hemorrhage (<1%) Anorexia (<1%) Flatulence (<1%) Dry mouth (<1%) Blood in stool (<1%) Alkaline phosphatase increased (<1%) LDH increased (<1%) SGOT increased (<1%) Jaundice (<1%) Cholestatic hepatitis (<1%) Buccal mucosa aphthous ulceration (<1%) Taste metallic (<1%) Pancreatitis (<1%) Atrial fibrillation (<1%) Pulmonary edema (<1%) Electrocardiogram change (<1%) Supraventricular tachycardia (<1%) Renal failure (<1%) Dysuria (<1%) Cystitis (<1%) Hematuria (<1%) Oliguria (<1%) Azotemia (<1%) Anuria (<1%) Nephritis interstitial (<1%) Nephrosis (<1%) Acute papillary necrosis (<1%) Angioedema (<1%) Purpura (<1%) Bruising (<1%) Hemorrhage (<1%) Thrombocytopenia (<1%) Hemolytic anemia (<1%) Aplastic anemia (<1%) Agranulocytosis (<1%) Pancytopenia (<1%) Depression (<1%) Disorientation (<1%) Seizures (<1%) Trigeminal neuralgia (<1%) Burning tongue (<1%) Diplopia (<1%) Optic neuritis (<1%) Exfoliative dermatitis (<1%) Toxic epidermal necrolysis (<1%) Stevens-Johnson syndrome (<1%) Alopecia (<1%) Anaphylaxis (<1%) Urticaria (<1%) Malaise (<1%) Insomnia (<1%) Tachycardia (<1%) Personality change (<1%) Lymphadenopathy (<1%) Mastodynia (<1%) Fever (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiovascular disorder (NOS) | 0.5% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Reaction skin | 1% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nasopharyngitis | 1.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Confusion | 1.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Upper respiratory infection | 1.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hearing decreased | 1.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Fatigue | 1.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Diarrhea | 1.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dyspepsia | 10% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Abdominal pain | 2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Reaction gastrointestinal | 2% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Blurred vision | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tremor | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Palpitations | 2.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Vomiting | 2.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dyspnea | 2.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Rash | 3.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pruritus | 4.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tinnitus | 4.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Sweating increased | 4.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Peripheral edema | 5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Asthenia | 5.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nervousness | 5.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dizziness | 6.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Constipation | 7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nausea | 7.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Somnolence | 8.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Headache | 8.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Acute papillary necrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Agranulocytosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Alkaline phosphatase increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Alopecia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Anaphylaxis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Angioedema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Anorexia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Anuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Aplastic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Atrial fibrillation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Azotemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Blood in stool | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Bruising | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Buccal mucosa aphthous ulceration | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Burning tongue | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Cholestatic hepatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Cystitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Depression | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Diplopia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Disorientation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dry mouth | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dysuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Electrocardiogram change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Exfoliative dermatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Fever | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Flatulence | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Gastritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Gastrointestinal hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hematuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hemolytic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Insomnia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Jaundice | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| LDH increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Lymphadenopathy | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Malaise | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Mastodynia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nephritis interstitial | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nephrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Oliguria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Optic neuritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pancreatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pancytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Personality change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pulmonary edema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Purpura | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Renal failure | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| SGOT increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Seizures | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Stevens-Johnson syndrome | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Supraventricular tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Taste metallic | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Thrombocytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Toxic epidermal necrolysis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Trigeminal neuralgia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Urticaria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. | 2010-09-16 |
|
| Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity. | 2010-09 |
|
| Electrokinetic supercharging focusing in capillary zone electrophoresis of weakly ionizable analytes in environmental and biological samples. | 2010-09 |
|
| Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry. | 2010-08 |
|
| Enantiomeric separation of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs by HPLC with hydroxypropyl-beta-cyclodextrin as chiral mobile phase additive. | 2010-08 |
|
| Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. | 2010-07-15 |
|
| A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. | 2010-07-08 |
|
| Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. | 2010-06 |
|
| Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens. | 2010-05-05 |
|
| Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. | 2010-03 |
|
| Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. | 2010-02-18 |
|
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | 2010 |
|
| PPARs in Irradiation-Induced Gastrointestinal Toxicity. | 2010 |
|
| Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids. | 2009-10 |
|
| Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. | 2009-10 |
|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009-09 |
|
| Combined use of chiral ionic liquid and CD for MEKC: Part II. Determination of binding constants. | 2009-08 |
|
| Antioxidant activity of NSAID hydroxamic acids. | 2009-06 |
|
| Using subcritical/supercritical fluid chromatography to separate acidic, basic, and neutral compounds over an ionic liquid-functionalized stationary phase. | 2009-04-17 |
|
| Chemoenzymatic and microbial dynamic kinetic resolutions. | 2009-04 |
|
| Synthesis of dehydroabietic acid-modified chitosan and its drug release behavior. | 2009-01-05 |
|
| The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations. | 2009-01 |
|
| The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats. | 2008-10 |
|
| Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage. | 2008-09-01 |
|
| Robust open tubular layer of S-ketoprofen imprinted polymer for chiral LC separation. | 2008-09 |
|
| Chiral separation of fluvastatin enantiomers by capillary electrophoresis. | 2008-08 |
|
| Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. | 2008-07 |
|
| Interactions between APP secretases and inflammatory mediators. | 2008-06-18 |
|
| A combination of statistical and analytical evaluation methods as a new optimization strategy for the quantification of pharmaceutical residues in sewage effluent. | 2008-04-21 |
|
| Efficient, selective, and green: catalyst tuning for highly enantioselective reactions of ethylene. | 2008-04-17 |
|
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | 2008 |
|
| Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. | 2008 |
|
| Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. | 2008 |
|
| Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. | 2008 |
|
| A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. | 2007-12-26 |
|
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | 2007-12 |
|
| Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. | 2007-11 |
|
| A peripatetic pediatrician's journey into pediatric rheumatology: Part II. | 2007-06-21 |
|
| Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis. | 2007-05-05 |
|
| Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion. | 2007-05-01 |
|
| Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? | 2007-05 |
|
| The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. | 2007-04-01 |
|
| Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. | 2007-03 |
|
| Fenoprofen and ketoprofen amides as potential antitumor agents. | 2007-03 |
|
| Enantioseparation by CE with vancomycin as chiral selector: Improving the separation performance by dynamic coating of the capillary with poly(dimethylacrylamide). | 2007-03 |
|
| Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. | 2007-01 |
|
| Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. | 2007-01 |
|
| Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. | 2006-11 |
|
| Prophylaxis of migraine. | 2006-09 |
|
| Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. | 2006-09 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:50 GMT 2025
by
admin
on
Mon Mar 31 18:00:50 GMT 2025
|
| Record UNII |
869607J16Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
29679-59-2
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
SUPERSEDED | |||
|
23666712
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY | |||
|
DBSALT001848
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY | |||
|
34691-31-1
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY | |||
|
DTXSID40956173
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY | |||
|
869607J16Q
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY | |||
|
C132138
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY | |||
|
1269550
Created by
admin on Mon Mar 31 18:00:50 GMT 2025 , Edited by admin on Mon Mar 31 18:00:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |